Study S000174

A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07466017
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 130
Start: 2026-04-02
Primary completion: 2027-04-30
Lead sponsor: Cascade Pharmaceuticals, Inc
Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH); Obesity
Interventions: DRUG:semaglutide; DRUG:CS060380; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:2024LP01824; OTHER:CS060380-MASH-CN-II-03

Registered primary outcomes

Percentage change in liver fat content from baseline to Week 36 (MRI-PDFF) [Baseline, Week 36]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012449	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. Newsome PN, The New England journal of medicine	2021	Randomized trial	PMID 33185364 DOI	registry reference BACKGROUND:33185364